Free Trial
NYSE:PEN

Penumbra (PEN) Stock Price, News & Analysis

$195.08
+4.28 (+2.24%)
(As of 10/8/2024 ET)

About Penumbra Stock (NYSE:PEN)

Key Stats

Today's Range
$190.51
$196.24
50-Day Range
$163.65
$210.12
52-Week Range
$148.00
$277.34
Volume
273,502 shs
Average Volume
382,432 shs
Market Capitalization
$7.56 billion
P/E Ratio
82.31
Dividend Yield
N/A
Price Target
$208.00
Consensus Rating
Moderate Buy

Company Overview

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
85th Percentile Overall Score

PEN MarketRank™: 

Penumbra scored higher than 85% of companies evaluated by MarketBeat, and ranked 162nd out of 994 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Penumbra has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Penumbra has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Penumbra's stock forecast and price target.
  • Earnings Growth

    Earnings for Penumbra are expected to grow by 39.00% in the coming year, from $2.59 to $3.60 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Penumbra is 82.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.10.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Penumbra is 82.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.30.

  • Price to Earnings Growth Ratio

    Penumbra has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Penumbra has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Penumbra's valuation and earnings.
  • Percentage of Shares Shorted

    6.78% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Penumbra has recently increased by 8.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Penumbra does not currently pay a dividend.

  • Dividend Growth

    Penumbra does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.78% of the outstanding shares of Penumbra have been sold short.
  • Short Interest Ratio / Days to Cover

    Penumbra has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in Penumbra has recently increased by 8.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Penumbra has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Penumbra this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for PEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Penumbra to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Penumbra insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,862,518.00 in company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Penumbra is held by insiders.

  • Percentage Held by Institutions

    88.88% of the stock of Penumbra is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Penumbra's insider trading history.
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

The Standard Oil of AI?
ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...
Penumbra (NYSE:PEN) Price Target Raised to $222.00
See More Headlines

PEN Stock Analysis - Frequently Asked Questions

Penumbra's stock was trading at $251.54 at the beginning of 2024. Since then, PEN stock has decreased by 22.4% and is now trading at $195.0850.
View the best growth stocks for 2024 here
.

Penumbra, Inc. (NYSE:PEN) issued its earnings results on Tuesday, July, 30th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.08. The company's revenue for the quarter was up 14.5% on a year-over-year basis.

Penumbra's Board of Directors authorized a stock repurchase plan on Tuesday, August 13th 2024, which permits the company to buy back $200,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 2.6% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

Top institutional shareholders of Penumbra include Handelsbanken Fonder AB (0.03%), Diversified Trust Co (0.03%), SG Americas Securities LLC (0.02%) and Park Avenue Securities LLC. Insiders that own company stock include Adam Elsesser, Arani Bose, Johanna Roberts, Harpreet Grewal, Bridget O'rourke, Surbhi Sarna, Don W Kassing and Thomas Wilder.
View institutional ownership trends
.

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Netflix (NFLX).

Company Calendar

Last Earnings
7/30/2024
Today
10/08/2024
Next Earnings (Confirmed)
10/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
4,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$209.42
High Stock Price Target
$263.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+6.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$90.95 million
Pretax Margin
-1.04%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$2.85 per share
Book Value
$30.55 per share

Miscellaneous

Free Float
36,827,000
Market Cap
$7.55 billion
Optionable
Optionable
Beta
0.54

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:PEN) was last updated on 10/8/2024 by MarketBeat.com Staff
From Our Partners